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Abstract
Background Critically ill patients frequently develop muscle atrophy and weakness in the intensive-care-unit setting [intensive
care unit-acquired weakness (ICUAW)]. Sepsis, systemic inflammation, and acute-phase response are major risk factors.
We reported earlier that the acute-phase protein serum amyloid A1 (SAA1) is increased and accumulates in muscle of ICUAW
patients, but its relevance was unknown. Our objectives were to identify SAA1 receptors and their downstream signalling
pathways in myocytes and skeletal muscle and to investigate the role of SAA1 in inflammation-induced muscle atrophy.
Methods We performed cell-based in vitro and animal in vivo experiments. The atrophic effect of SAA1 on differentiated
C2C12 myotubes was investigated by analysing gene expression, protein content, and the atrophy phenotype. We used the
cecal ligation and puncture model to induce polymicrobial sepsis in wild type mice, which were treated with the IкB kinase
inhibitor Bristol-Myers Squibb (BMS)-345541 or vehicle. Morphological and molecular analyses were used to investigate the
phenotype of inflammation-induced muscle atrophy and the effects of BMS-345541 treatment.
Results The SAA1 receptors Tlr2, Tlr4, Cd36, P2rx7, Vimp, and Scarb1 were all expressed in myocytes and skeletal muscle.
Treatment of differentiated C2C12myotubes with recombinant SAA1 caused myotube atrophy and increased interleukin 6 (Il6) gene
expression. These effects were mediated by Toll-like receptors (TLR) 2 and 4. SAA1 increased the phosphorylation and activity of the
transcription factor nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells (NF-κB) p65 via TLR2 and TLR4 leading to an
increased binding of NF-κB to NF-κB response elements in the promoter region of its target genes resulting in an increased
expression of NF-κB target genes. In polymicrobial sepsis, skeletal muscle mass, tissue morphology, gene expression, and
protein content were associated with the atrophy response. Inhibition of NF-κB signalling by BMS-345541 increased survival
(28.6% vs. 91.7%, P < 0.01). BMS-345541 diminished inflammation-induced atrophy as shown by a reduced weight loss of
the gastrocnemius/plantaris (vehicle: 21.2% and BMS-345541: 10.4%; P < 0.05), tibialis anterior (vehicle: 22.7% and
BMS-345541: 17.1%; P < 0.05) and soleus (vehicle: 21.1% and BMS-345541: 11.3%; P < 0.05) in septic mice. Analysis of the
fiber type specific myocyte cross-sectional area showed that BMS-345541 reduced inflammation-induced atrophy of slow/type I
and fast/type II myofibers compared with vehicle-treated septic mice. BMS-345541 reversed the inflammation-induced atrophy
program as indicated by a reduced expression of the atrogenes Trim63/MuRF1, Fbxo32/Atrogin1, and Fbxo30/MuSA1.
Conclusions SAA1 activates the TLR2/TLR4//NF-κB p65 signalling pathway to cause myocyte atrophy. Systemic inhibition of
the NF-κB pathway reduced muscle atrophy and increased survival of septic mice. The SAA1/TLR2/TLR4//NF-κB p65 atrophy
pathway could have utility in combatting ICUAW.
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Introduction
Critically ill intensive care unit (ICU) patients often develop
muscle atrophy and weakness [ICU-acquired weakness
(ICUAW)] with increased morbidity and mortality.1,2 The
incidence of ICUAW is up to 90% in severe sepsis patients.3
Sequels persists for up to 5 years after discharge,
underscoring substantial morbidity.4 Additionally, ICUAW is
associated with high costs for the health care system.4,5
Inflammation and sepsis clearly increase the risk for ICUAW,
and inflammatory cytokines are associated with the incidence
of ICUAW.6,7 Skeletal muscle and skeletal myocytes are
targeted by inflammatory cytokines, such as interleukin 1β
(IL1β) and IL6,8–10 causing myocyte atrophy.8,11,12 Our
attention was drawn to serum amyloid A1 (SAA1) that is
associated with inflammation and acute-phase responses
during sepsis.11,13While the main source of SAA1 is the
liver,13 IL6 increases SAA1 expression and secretion in
muscle.8,11,14 We earlier showed that SAA1 expression is
greatly increased in ICUAW and that SAA1 accumulates in
the myocyte membrane and in muscular interstitium.11
These findings were also observed in other studies.15–19
Nonetheless, a role of SAA1 as a perpetrator rather than a
mere biomarker in ICUAW is imperfectly defined.20
SAA1 is produced by various tumours21–23 and is also
associated with muscle wasting in cancer cachexia in mice.24
SAA1 cooperates with IL6 to mediate angiotensin II-induced
muscle atrophy,9 which is important for muscle wasting in
heart failure patients. SAA1 receptors have been described
in immune cells, including the purinergic receptor P2X7
(P2RX7), the CD36 receptor (CD36), the scavenger receptor
class b member 1 (SCARB1), the VCP interacting membrane
selenoprotein (VIMP), and Toll-like receptors (TLR) 2 and
4.25–31 SAA1 activates the NLRP3 inflammasome via P2RX7
and thereby promotes IL1β activation and release from
mouse and human macrophages.25 SAA1 also increases IL6
and TNF expression by activating the CD36 receptor in rat
macrophages and human embryonic kidney cells.26 SCARB1
mediates internalization of SAA in hepatocytes, and VIMP
acts as an SAA1-receptor in a mouse model of type 2
diabetes.27,28 In mouse macrophages, SAA1 was shown to
increase pro-inflammatory cytokines, such as IL23α and
tumor necrosis factor (TNF) via TLR2, and to increase nitric
oxide via TLR4.30–32 Importantly, SAA1 increases IL6
expression via TLR2 and TLR4 and activates the nuclear
factor ‘kappa-light-chain-enhancer’ of activated B-cells
(NF-κB) signalling pathway in dermal fibroblasts.33 However,
whether or not the TLR2/TLR4/NF-κB signalling pathway
plays a role in SAA1-induced myocyte atrophy in vitro and
sepsis-induced muscle atrophy in vivo is not known. We
demonstrate that SAA1 acts on myocytes to cause atrophy
by the TLR2/TLR4/NF-κB pathway. We also show that
inhibition of NF-κB by Bristol-Myers Squibb (BMS)-345541
increases survival and diminishes skeletal muscle atrophy
in septic mice. We suggest that SAA1 via activation of the
TLR2/TLR4/NF-κB atrophy pathway is mechanistically
important in ICUAW.
Methods
Patient samples
The institutional ethics committee of the Charité approved
the study; it has therefore been performed in accordance
with the ethical standards laid down in the 1964 Declaration
of Helsinki and its later amendments. Written informed
consent was obtained from legal proxy (ICU patients), or
the patients themselves (Charité EA2/061/06; http://www.
controlled-trials.com, ISRCTN77569430). Clinical data were
reported previously.11 Biopsy specimens were obtained at
Day 15 after ICU admission; control samples were acquired
from patients undergoing elective orthopaedic surgery as
described elsewhere.11,34,35
Animal model
The Landesamt für Gesundheit und Soziales, Berlin, Germany,
approved the animal studies (G207/13, G129/12). Cecal
ligation and puncture (CLP) surgery was performed to induce
polymicrobial sepsis in 18-week-old male C57BL/6J mice as
recently described.11,36,37 Sham mice were treated identically
except for CLP (Supporting Information).
Molecular and cell biology analysis
Routine techniques were performed as previously
shown11,12,35,37–40 and are outlined (Supporting Information).
Cell culture experiments with BMS-345541
We used BMS-345541 to investigate if NF-κB inhibition
prevents sepsis-induced muscle atrophy in the CLP mouse
model in vivo.41 BMS-345541 (4(2’-aminoethyl)amino-1,8-
dimethylimidazo(1,2-a)quinoxaline; CAS-number: 547757-
23-3) is a highly selective cell permeable IκB kinase (IKK)
2 and IKK-1 inhibitor, which blocks NF-κB-dependent
transcription; it was produced by BMS and purchased
from abcam (ab 144822). BMS-345541 was previously shown
to reduce CLP and LPS-induced lung injury,42,43 to reduce
inflammation in rats with spinal cord injury, and to suppress
inflammation in a model of cardiac graft rejection.44,45
Due to its high bioavailability41 and its anti-inflammatory
characteristics without impairing immune cell activation42
and bacterial clearance, BMS-345541 was well suited for
our studies. A 2.5 mM stock solution of BMS-345541
dissolved in 10% DMSO was prepared for all cell culture
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experiments. For short-term treatment, a final concentration
of 25 μM BMS-345541 was used because Burke et al.41
showed that this concentration abolished lipopolysaccharide
(LPS)-induced production of TNF, IL1β, IL8, and IL6 in
THP-1 cells, a human leukemic monocyte cell line.
Likewise, 25 μM BMS-345541 abolished TNF-stimulated
IκBα-phosphorylation.41 For long-term treatment of
myocytes (up to 72 h), we used 5 μM BMS-345541. This
concentration was chosen because the NF-κB pathway is
vital for cell function, and its complete inhibition over 72 h
provokes toxic side effects. However, 5 μM BMS-345541
was shown to completely inhibit IKK-2, reduce IKK-1 activity
by approximately 50%, and substantially decrease
LPS-induced production of TNF, IL 1β, IL-8, and IL-6 in THP 1
cells41; 5 μM BMS-345541 was shown to inhibit
IκBα-phosphorylation in the prostate cancer cell line PC-3.46
Anti-MuRF1 antibody
We generated a MuRF1 specific antibody against the
C-terminal Mus musculus MuRF1 cDNA fragment (amino
acids 185-355). The specificity of the antibody was tested
by immunoblotting tissue lysates of tibialis anterior from
wild type, Trim63/MuRF1 mutant and Trim54/MuRF3//Trim
63/MuRF1 double mutant mice and of lysates from C2C12
cells following siRNA mediated knockdown of MuRF1.
For more information about the antibody please refer to
Nowak et al.47
Statistical tests
All experiments were performed independently and at
least three times using biological triplicates each. The
Mann–Whitney or two-sided Student’s t-test was used to
compare quantitative RT-PCR gene expression data from
mouse and cell culture samples. Distribution of myotube
diameter of C2C12myotubes were analysed by the two-sided
Student’s t-test. Survival curves were compared with a
Mantel–Cox test. Differences were considered statistically
significant at P < 0.05. Data are shown as mean ± standard
error of the mean (SEM) in bar plots. GraphPad Prism®
program (GraphPad software, version 6.0), Adobe Illustrator,
version 16.0.0, and Photoshop, version 13.0, were used for
plots and statistical calculations.
Results
Serum amyloid A1, Toll-like receptors, and NF-κB
We quantitated the expression of Tlr2, Tlr4, Cd36, P2rx7,
Vimp, and Scarb1 in differentiated C2C12 myotubes, and
tibialis anterior and gastrocnemius/plantaris by quantitative
real-time polymerase chain reaction (qRT-PCR). All SAA1
receptors investigated were expressed in myocytes and
skeletal muscle (Figure 1A and 1B). We treated differentiated
C2C12 myotubes with recombinant SAA1 and vehicle
respectively and quantitated the expression of those SAA1
receptors by qRT-PCR. We found an upregulation of Tlr2
(5.4-fold, P < 0.05) and a downregulation of Vimp (0.9-fold,
P < 0.05), whereas the expression of Tlr4, Cd36, P2rx7, and
Scarb1 remained unchanged (Figure 1A).
To investigate if SAA1 causes atrophy by directly increasing
the expression of F-box only protein 30 (Fbxo30; encoding
muscle ubiquitin ligase of the SCF complex in atrophy-1,
MuSA1), Fbxo32 (encoding Atrogin1), and Trim63 (encoding
MuRF1), which are bona fide atrogenes48,49, SAA1 led to an
increase in Fbxo32 expression (P < 0.05), whereas the
expression of Fbxo30 and Trim63 remained unchanged in
differentiated C2C12 myotubes (Figure 1A).
To investigate if polymicrobial sepsis affects the expression
of SAA receptors, we studied their expression in tibialis
anterior and gastrocnemius/plantaris of mice subjected to
CLP surgery. Muscle of sham-operated mice was used as
control. We found an increased expression of Tlr2, Tlr4,
Cd36, and Vimp in both muscles of CLP compared with
sham-operated mice. In contrast, P2rx7 was reduced in
gastrocnemius/plantaris but remained unchanged in tibialis
anterior of septic mice. Sepsis had no effect on Scarb1
expression in both muscles investigated (Figure 1B). In order
to investigate if the atrophy program is activated in skeletal
muscle during sepsis, we quantitated the expression of
Fbxo30, Fbxo32, and Trim63 in both muscles of sham and
CLP mice. Fbxo30, Fbxo32, and Trim63 expression was
increased in both muscles of septic mice, compared with
sham controls, indicating that sepsis leads to an activation
of the atrophy program in muscle (Figure 1B). Earlier, we
had shown that ICUAW patients showed elevated amounts
of SAA1 in skeletal muscle compared with controls.11
Therefore, we investigated whether or not TLR2 and TLR4
are also upregulated in vastus lateralis of ICUAW patients
and used biopsy specimens from vastus lateralis of patients
that underwent elective orthopaedic surgery as a control.11
QRT-PCR showed a significant upregulation of TLR2 and
TLR4 in muscle of ICUAW patients compared with controls
(Figure 1C). In summary, our data show that all SAA receptors
investigated are expressed in cultivated myocytes and in
mouse skeletal muscle. The expression of Tlr2, Tlr4, Cd36,
and Vimp increased in skeletal muscle of septic mice. Because
SAA1 induced the expression of Tlr2 in cultivated muscle cells
and we found an increased expression of Tlr2 and Tlr4 in
muscle of septic mice and critically ill patients, we focused
on these SAA1 receptors for further analyses.
To test the hypothesis that SAA1 mediates its atrophic
effects through TLR2 and TLR4 on myocytes, we treated
C2C12myotubes with SAA1, performed immunocytochemistry
with anti-myosin antibody, and measured myotube diameters
as indicator for atrophy. We found that SAA1-treatment
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caused myotube atrophy (Figure 2A) as indicated by a
leftward-shift of the frequency-distribution histogram
(Figure 2B) and a decrease in the mean myotube diameter
(Figure 2E). Recently, we reported that inflammation causes
a decrease in myosin heavy chain (MyHC) proteins in
muscle and that the ubiquitin proteasome system, especially
the muscle specific E3-ligase MuRF1, was involved.12,34 We
therefore next investigated whether SAA1-induced atrophy
coincided with a decrease in MyHC and an increase in
MuRF1 protein content. Western blot analysis showed that
SAA1-treatment led to a decrease in Myh7 and an increase
in MuRF1 protein contents in C2C12 myotubes (Figure 2F).
To test if SAA1-induced atrophy is mediated by TLR2 and
TLR4, we exposed C2C12 myotubes to SAA1 in the presence
or absence of anti-TLR2 and anti-TLR4 antibody, respectively.
Immunocytochemistry and measurements of myotube
diameters showed that anti-TLR2 and anti-TLR4 antibody
attenuated SAA1-induced atrophy (Figure 2B and 2E). To
investigate if both TLR-receptors individually are capable
to cause myocyte atrophy, we exposed C2C12 myotubes to the
TLR2-agonist Pam3Csk4 and the TLR4-agonist lipopolysaccharide
(LPS), respectively, and tested their atrophic response after
addition of either anti-TLR2 or anti-TLR4 antibody. Both
Pam3Csk4 and LPS caused myotube atrophy, which was
blocked by their respective inhibitors. These data indicate
that TLR2 and TLR4 are equally effective to induce myotube
atrophy (Figure 2A and 2C–2E).
Because TLR2 and TLR4 activate NF-κB signalling in
immune cells,50,51 we investigated if SAA1 activates NF-κB
via TLR2 and TLR4 in myocytes. Western blot analysis
showed that SAA1-treatment caused an increased
phosphorylation of the NF-κB transcription factor p65 in
C2C12 myotubes (Figure 3A). Electrophoretic mobility shift
assay (EMSA) revealed that SAA1-treatment led to an
increased binding of activated NF-κB p65 to NF-ĸB response
elements (NRE) (Figure 3B). Addition of an anti-p65 antibody
to the EMSA-assay resulted in a super-shift of the NF-κB
p65/NRE complex underscoring the specificity of this assay
(Figure 3B). To further investigate the NF-κB p65 pathway,
we used the IκB kinase (IKK) inhibitor BMS-345541 that
Figure 1 Expression of SAA1 receptors in C2C12 myotubes and skeletal muscle. (A) C2C12 myocytes were differentiated for 5 days and treated for 1 h
with human recombinant SAA1 (20 μg/mL). qRT-PCR analysis of SAA1 receptors Tlr2, Tlr4, Cd36, P2rx7, Vimp, Scarb1, and the atrogenes Fbxo30,
Fbxo32, and Trim63. mRNA expression was normalized to Gapdh. Values of vehicle treated cells were set to 1 and are indicated as dotted line.
Cd36 indicates cluster of differentiation 36; Fbxo30, F-box protein 30; Fbxo32, F-box protein 32; P2rx7, purinergic receptor P2X7; Scarb1, scavenger
receptor class b member 1; Tlr2 indicates Toll-like receptor 2; Trim63, tripartite motif containing 63; Vimp, VCP interacting membrane selenoprotein.
(B) Twelve-week-old male WT mice were subjected to Sham (n = 3) or CLP (n = 5) surgery for 24 h. Expression of the SAA1 receptors Tlr2, Tlr4,
Cd36, P2rx7, Vimp, and Scarb1 and the atrogenes Fbxo30, Fbxo32, and Trim63 was quantitated by qRT-PCR in tibialis anterior and gastrocnemius/
plantaris. mRNA expression was normalized to stably expressed Gapdh. Gene expression of sham treated mice was set to 1 and is indicated as dotted
line. (C) qRT-PCR analyses of TLR2 and TLR4 expression in control (no ICU subjects; n = 5) and CIM (15 days after ICU admission; n = 5) patients. GAPDH
expression was used as a reference. Data are presented as mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.
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Figure 2 SAA1 causes atrophy of C2C12 myotubes via Toll-like receptor (TLR) 2 and 4, in an NF-κB dependent manner. C2C12 cells were differentiated
for 5 days and treated with SAA1 (10 μg/mL), Pam3Csk4 (50 ng/mL), lipopolysaccharide (LPS; 1 μg/mL), anti-TLR2 antibody (10 μg/mL), anti-TLR4
antibody (20 μg/mL), or BMS-345541 (5 μM), as indicated, for 72 h. (A) Immunohistochemistry with anti-myosin heavy chain 4 (MyHC4, clone
MF20) antibody. Nuclei were stained with DAPI. Scale bar = 100 μm. (B–D) Frequency distribution histograms of myotube diameters are shown
(n = 100 cells per condition). (E) Mean myotube diameter. Data are presented as mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. (F) Western
blot analysis with anti-myosin heavy chain 7 (MyHC7; clone NOQ7.5.4D) and anti-MuRF1antibody. Specificity of the anti-MuRF1 antibody was tested by
western blot analysis using tissue lysates of tibialis anterior muscle from wild type, Trim63/MuRF1mutant and Trim54/MuRF3//Trim63/MuRF1 double
mutant mice and of lysates from C2C12 cells following siRNA mediated knockdown of MuRF1 (data not shown). For more information, please refer to
Nowak et al.47 GAPDH was used as loading control.
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abolishes IKK-dependent phosphorylation of p65 and of IκBα
and subsequent degradation of IκBα and activation of NF-κ
B.41 We found that SAA1-induced phosphorylation of NF-κB
p65 was attenuated by BMS-345541 (Figure 3A) indicating
that IKK is involved in this process. Likewise, BMS-345541
abolished SAA1-induced NF-κB p65/NRE complex formation
and the super-shift in EMSA (Figure 3B).
Although NF-κB p65 mediates denervation and tumour-
induced atrophy52,53 and its inhibition prevents muscle
atrophy in mice with acute lung injury,54 whether or not
NF-κB p65 mediates SAA1-induced atrophy is unknown. We
therefore treated C2C12myotubes with SAA1 in the presence
or absence of BMS-345541 and quantitated the atrophic
response. Indeed, BMS-345541 abolished SAA1-induced
atrophy (Figure 2A, 2B, and 2E), which was accompanied by
an increase in Myh7 and a decrease in MuRF1 proteins as
shown by western blot (Figure 2F). These data indicate that
SAA1-induced atrophy is mediated by TLR2 and TLR4 and
that the NF-κB p65 pathway is involved.
Recently, we reported that ICUAW patients and septic
mice show increased muscular IL6 and SAA1 levels.11
Interestingly, IL6-treatment causes an increase in SAA1
expression in myocytes,11 and conversely SAA1 induces IL6
in fibroblasts.33 These data suggested a positive feedback
loop between SAA1 and IL6. To test if this feedback loop is
present in myocytes and depends on TLR2-mediated and
TLR4-mediated NF-κB activation, we investigated if SAA1
induces IL6 in these cells. Using qRT-PCR, we found that
SAA1 increased Il6 expression in C2C12 myotubes. Anti-TLR2
and TLR4 antibodies, as well as BMS-345541 treatment,
attenuated SAA1-induced Il6 expression (Figure 3C).
ELISA-based quantification of the IL6 content in C2C12 cell
culture supernatant revealed that SAA1-induced IL6-secretion
was diminished by BMS-345541 but remained unaffected by
Figure 3 SAA1 increases Il6 expression and secretion via Toll-like receptor (TLR) 2, TLR4 and NF-κB p65. (A) C2C12 cells were treated with SAA1
(10 μg/mL) for 25 min in the presence or absence of BMS-345541 (25 μM). Western blot analysis with anti-phospho p65 antibody and anti-p65
antibody are shown. GAPDH was used as loading control. (B) C2C12 cells were treated with SAA1 (10 μg/mL) for 25 min in the presence or absence
of BMS-345541 (25 μM). NF-кB p65/NF-κB-response element complex formation was analysed by EMSA. (C) Five-day-differentiated C2C12 myotubes
were preincubated with anti-TLR2 antibody (10 μg/mL), anti-TLR4 antibody (20 μg/mL), or BMS-345541 (25 μM) as indicated. Afterwards cells were
treated with SAA1 (10 μg/mL), LPS (1 μg/mL), or Pam3Csk4 (50 ng/mL) as indicated. qRT-PCR analysis of Il6. mRNA expression was normalized to
Gapdh. Control values were set to 1 and are indicated as dotted line. Data are presented as mean fold change ± SEM. (D) Quantification of IL6 in cell
culture supernatants by ELISA. Cells were preincubated with anti-TLR2 antibody (10 μg/mL), anti-TLR4 antibody (20 μg/mL), or BMS-345541 (25 μM) as
indicated prior to SAA1 treatment (10 μg/mL). Data are presented as the mean ± SEM. n.d., not detectable; *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.
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anti-TLR2 and TLR4 antibody (Figure 3D). To further test if
TLR2 and TLR4 activation regulate both IL6 expression and
secretion, we treated C2C12 myotubes with the TLR2-agonist
Pam3Csk4 and the TLR4-agonist lipopolysaccharide (LPS),
respectively, in the presence or absence of anti-TLR2 or TLR4
antibody. The anti-TLR2 antibody reduced Pam3Csk4-induced
IL6 expression and secretion. In contrast, the anti-TLR4 antibody
did not inhibit LPS-induced IL6-secretion (Figure 3C and 3D).
BMS-345541 attenuated Pam3Csk4-induced and LPS-induced
Il6 expression and secretion (Figure 3C and 3D). These data
suggest that SAA1-induced Il6 expression is mediated by TLR2
and TLR4 and that the NF-κB p65 pathway is involved in
this process.
Sepsis-induced muscle atrophy is reduced by
BMS-345541 treatment in vivo
Because our data indicated that SAA1 causes myocyte
atrophy via the TLR2/TLR4/NF-κB pathway, we hypothesized
that inhibition of the NF-κB pathway could prevent muscle
atrophy in septic mice. To test this hypothesis, we subjected
male WT mice to sham or CLP surgery and treated them
with either vehicle or BMS-345541, which were administered
by oral gavage.41 BMS-345541 treatment resulted in
highly significant improvement of survival of CLP-operated
compared with vehicle-treated septic mice (Figure 4A).
Sepsis-induced reduction in tibialis anterior (25%, P <
0.05), gastrocnemius/plantaris (49%, P < 0.05), and soleus
(45%, P < 0.05) weights was inhibited by BMS-345541.
Sepsis caused a reduction in heart weight as well (sham +
vehicle vs. sham + BMS-345541: 20.4%, P < 0.05; sham +
BMS-345541 vs. CLP + BMS-345541: 14.4%, P < 0.05).
BMS-345541 treatment was accompanied by a reduced
cardiac weight loss which was not significant (P = 0.3)
(Figures 4B and S1). As expected, western blot analysis
showed an increased NF-κB p65 phosphorylation in tibialis
anterior of septic compared with sham operated mice,
which was attenuated by BMS-34551 (Figure 4C). Our data
show that inhibition of sepsis-induced NF-κB activation by
BMS-345541 improves survival and attenuates muscular
weight loss during sepsis.
Recently, others and we showed that primarily fast-twitch
fibers undergo atrophy in ICUAW patients and septic
mice.12,34 Therefore, we tested if BMS-345541 protects
fast/type-II myofibers from atrophy in sepsis. Analyses of
tibialis anterior and gastrocnemius/plantaris cross sections
and quantification of myocyte cross-sectional area (MCSA)
showed that CLP treated animals had a pronounced atrophy
of fast/type-II myofibers (Figures 5A, 5B, 6A, and 6B). CLP
operated mice that were treated with BMS-345541 showed
less myofiber atrophy compared with vehicle-treated CLP
mice as indicated by a significantly lower reduction in MCSA
in tibialis anterior and gastrocnemius/plantaris (Figures 5A,
5B, 6A, and 6B). Because the soleus contains both
slow/type-I and fast/type-II myofibers, we performed
histological cross sections of the soleus and quantitated
the MCSA for both fiber types following metachromatic
ATPase staining. We found a reduction in the MCSA of
slow/type-I (sham + vehicle vs. CLP + vehicle: 17%, P <
0.001; sham + BMS-345541 vs. CLP + BMS-345541: 15%,
P < 0.001) and fast/type-II myofibers (sham + vehicle vs.
CLP + vehicle: 28%, P < 0.001; sham + BMS-345541 vs.
CLP + BMS-345541: 20%, P < 0.001). We found a
significantly lower MCSA reduction of slow/type-I (P < 0.001)
and fast/type-II myofibers (P < 0.001) in soleus of
BMS-345541-treated septic mice (Figure 7A and 7B). Our results
show that fast/type-II myofibers are more susceptible than
slow/type-I myofibers to sepsis-induced atrophy and that
BMS-345541 treatment protects from sepsis-induced myofiber
atrophy in mice in vivo.
We had also observed that an increased protein
degradation and a decreased protein synthesis contributes
to muscle atrophy in ICUAW patients and septic mice.12
To test if the inhibition of septic muscle atrophy by
BMS-345541 was accompanied by an improved protein
homeostasis, we quantitated Myh4 and Myh7 expression in
tibialis anterior by qRT-PCR. Sepsis led to a decreased Myh4
expression (sham + vehicle vs. CLP + vehicle: 56%, P <
0.01; sham + BMS-345541 vs. CLP + BMS-345541: 15%,
n.s.), which was attenuated by 34% by BMS-345541 (P <
0.05). Myh7 expression followed the same trend that
did not reach significance (Figure 8A). To investigate the
effect of BMS-345541 treatment on protein degradation,
we quantified the expression of Fbxo30, Fbxo32, and
Trim63 in tibialis anterior and gastrocnemius/plantaris. CLP
significantly increased Fbxo32 and Trim63 expression, and
BMS-345541 treatment attenuated this response in both
muscles. Fbxo30 was also significantly increased in tibialis
anterior and gastrocnemius/plantaris of vehicle-treated
septic mice but remained unchanged in BMS-345541
treated animals (Figure 8B). The Atrogin1/Fbxo32 and
MuRF1/Trim63 protein content increased during sepsis in
tibialis anterior and BMS-345541 attenuated this response
(Figure 8C). Our data indicate that the attenuation of
sepsis-induced atrophy by BMS-345541 involved an improved
protein homeostasis.
Increased NF-κB activity plays a pivotal role for the
regulation of immune cell function during a bacterial
insult.55,56 Indeed, immune cell activation is important
for bacterial clearance in sepsis.42,57 To investigate if
BMS-345541 treatment affected immune cells, we performed
flow cytometric analyses of splenocytes. Sepsis caused
an increase in spleen weight, which was unaffected by
BMS-345541 (Figure S2). The total numbers and proportions
of dendritic cells (CD11chiMHCII+), B-cells (CD19+B220+), and
natural killer cells (NK, NK1.1+) decreased (Figure S3A–S3C),
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while neutrophil numbers (Ly6G+) increased in septic mice
(Figure S3D). We also observed a significant reduction in
the proportions of CD3+ T-cells, which was due to decreased
percentages of CD4+ helper T-cells in the spleens of septic
mice, whereas CD8+ cytotoxic T-cells remained unchanged
(Figure S4A–S4C). Finally, percentages of Foxp3+CD25+CD4+
regulatory T-cells were increased, and Foxp3-/CD4+ effective
T-cells were decreased in the spleen of septic mice, and
both T-cell subpopulations were activated, as shown by
the increased CD69 expression. In the case of vehicle-treated
animals, this increase did not reach significance (Figure
S5A–S5C). Notably, BMS-345541 treatment had no significant
effect on sepsis-induced alterations of numbers, proportions,
and activation of splenic immune cells, indicating that
its strong impact on survival and muscle atrophy were
independent of the immune cell responses to sepsis.
Figure 4 BMS-345541 treatment increases survival and attenuates muscle atrophy in septic mice in vivo. (A–C) Eighteen-week-old male WT mice were
either sham or CLP operated as indicated. Sham-operated and CLP-operated mice were divided into two groups each which then received either
vehicle (5% TWEEN 20 in distilled H2O, pH 7.4) or BMS-345541 30 min prior to (30 mg/kg body weight) and 6 h after (15 mg/kg body weight) surgery
p.o.; experimental groups are as follows: sham + vehicle (n = 6), CLP + vehicle (n = 14), sham + BMS-345541 (n = 6), and CLP + BMS-345531 (n = 12).
After 96 h, all mice were sacrificed. (A) Survival of all animals. Statistical analysis was performed using the log-rank test. **P ≤ 0.01. (B) Weights of
tibialis anterior, gastrocnemius/plantaris, soleus, and the heart normalized to tibia length. Data are presented as mean ± SEM. *P ≤ 0.05. (C) Western
blot analysis of tibialis anterior with anti-phospho-p65 and anti-p65 antibody. GAPDH was used as loading control.
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Discussion
Serum amyloid A1 (SAA1) accumulation in muscle is
associated with ICUAW.11 However, neither the putative
receptors for SAA1 nor the involved pathways have been
described in myocytes or muscle. We identified Toll-like
receptors 2 and 4 as SAA1 receptors on myocytes in vitro.
We show that SAA1 via TLR2 and TLR4 activates the NF-κB
p65 pathway that mediates the SAA1-response of myocytes.
Specifically, we demonstrate that SAA1-induced myocyte
atrophy is attenuated by blocking either TLR2 or TLR4 or by
inhibition of the NF-κB p65 pathway with BMS-345541
in vitro. We show that inhibition of NF-κB activity by
BMS-345541 increased survival and reduced muscle atrophy
in a mouse model of polymicrobial sepsis in vivo. Our findings
suggest that inhibition of NF-κB during sepsis may increase
survival and attenuate SAA1-induced muscle atrophy.
Although the function of SAA1 is well described for
liver and immune cells,58 any role in muscle is less well
understood. For example, SAA1 can bind to several receptors,
such as TLR2, TLR4, CD36, P2RX7, VIMP, and SCARB1, which
are expressed on hepatocytes, keratinocytes, fibroblasts,
and macrophages.25–28,30,31,33,59 Whether or not these
receptors are involved in SAA1 signalling in myocytes was
Figure 5 BMS-345541 treated mice are protected from sepsis-induced atrophy of the tibialis anterior muscle. Eighteen-week-old male WT mice were
either sham or CLP operated as indicated. Per surgical group mice were divided into two groups each which than received either vehicle (5% TWEEN 20
in distilled H2O, pH 7.4) or BMS-345541 30 min prior to (30 mg/kg body weight) and 6 h after (15 mg/kg body weight) surgery p.o.; experimental
groups are as follows: sham + vehicle (n = 6), CLP + vehicle (n = 4), sham + BMS-345541 (n = 6), and CLP + BMS-345531 (n = 11). After 96 h, the mice
were sacrificed. (A) Haematoxylin and eosin (H&E) and ATPase staining of histological cross sections from tibialis anterior (TA). Scale bar = 100 μm. (B)
Quantification of fast/type II myofiber cross-sectional area (MCSA) from metachromatic ATPase staining (as depicted in panel A). One hundred
myofibers per animal were measured. ***P ≤ 0.001.
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uncertain. Here, we show that TLR2, TLR4, CD36, P2RX7,
VIMP, and SCARB1 are also expressed in myocytes and
muscle and that muscular expression of TLR2, TLR4, CD36,
and VIMP increases during sepsis. We found that SAA1
causes myocyte atrophy in vitro, which was mediated by
TLR2 and TLR4 as well as NF-κB. Together with our recent
report showing that SAA1 expression, synthesis, and
secretion increase in muscle of ICUAW patients and septic
mice, our data indicate that muscle is targeted by SAA1 in a
paracrine manner and that TLR2, TLR4, and NF-κB are
involved in SAA1-induced atrophy.
TLR2 was shown to mediate SAA1-induced Il6 expression in
fibroblasts33 and to mediate Il6 expression and atrophy in
myocytes.8 Activation of TLR2 and TLR4 by specific agonists
were found to mediate IL6 secretion from C2C12myotubes.60
Recently, we reported that SAA1 increases Il6 expression in
murine and human myocytes in vitro.11 In addition, IL6
expression is increased in muscle of ICUAW patients and
Figure 6 BMS-345541 treated mice are protected from sepsis-induced muscle atrophy of the gastrocnemius/plantaris. Eighteen-week-old male WT
mice were either sham or CLP operated as indicated. Per surgical group, mice were divided into two groups each which then received either vehicle
(5% TWEEN 20 in distilled H2O, pH 7.4) or BMS-345541 30 min prior to (30 mg/kg body weight) and 6 h after (15 mg/kg body weight) surgery p.o.;
experimental groups are as follows: sham + vehicle (n = 6), CLP + vehicle (n = 4), sham + BMS-345541 (n = 6), and CLP + BMS-345531 (n = 11). After
96 h, the mice were sacrificed. (A) Haematoxylin and eosin (H&E) and ATPase stain of histological cross sections from gastrocnemius/plantaris (GP).
Scale bar = 100 μm. (B) Quantification of fast/type II myofiber cross-sectional area (MCSA) from metachromatic ATPase staining (as depicted in panel A).
One hundred myofibers per animal were measured. ***P ≤ 0.001.
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septic mice.11,12 We found that muscular TLR2 and TLR4
expression is increased during sepsis in patients and mice,
that SAA1 increases Tlr2 and Tlr4 expression in myotubes,
and that SAA1 via TLR2 and TLR4 increases Il6 expression
in myocytes. Based on these data, we hypothesize that
during sepsis, SAA1 participates in a positive feedback loop
of self-perpetuating inflammation in muscle not only by
increasing IL6 expression but also by increasing the
expression of its own receptors, which further augments IL6
expression. Moreover, we showed that SAA1 induces IL6
expression in myocytes and vice versa, which further
supports a self-augmenting positive feedback loop in muscle
during inflammation. Considering that SAA1 accumulation
correlates with muscle atrophy in ICUAW patients, these
feedback mechanisms could worsen IL6-mediated atrophy.
Because LPS elevates NF-κB-dependent gene expression
via TLR4,61,62 we investigated whether SAA1 activates
this pathway in myocytes. We show that SAA1 activates the
canonical NF-κB p65 signalling pathway via TLR2 and TLR4
resulting in an increased expression of NF-κB p65 target
genes and myocyte atrophy. For our analyses, we used the
highly selective IKK inhibitor BMS-345541. IKK phosphorylates
IκBα and NF-κB p65, leading to the proteasomal degradation
of IκBα and release of active NF-κB.63 Indeed, BMS-345541
Figure 7 BMS-345541 treated mice are protected from sepsis-induced muscle atrophy of the soleus. Eighteen-week-old male WT mice were either
sham or CLP operated as indicated. Per surgical group, mice were divided into two groups each which then received either vehicle (5% TWEEN 20
in distilled H2O, pH 7.4) or BMS-345541 30 min prior to (30 mg/kg body weight) and 6 h after (15 mg/kg body weight) surgery p.o.; experimental
groups are as follows: sham + vehicle (n = 6), CLP + vehicle (n = 4), sham + BMS-345541 (n = 6), and CLP + BMS-345531 (n = 11). After 96 h, the mice
were sacrificed. (A) Haematoxylin and eosin (H&E) and ATPase stain of histological cross sections from soleus. Scale bar = 100 μm. (B) Quantification of
slow/type I and fast/type II myofiber cross-sectional area (MCSA) from metachromatic ATPase staining (as depicted in panel A). One hundred
myofibers per animal were measured. ***P ≤ 0.001.
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decreased SAA1-induced NF-κB p65 phosphorylation,
inhibited formation of NF-κB-DNA complexes, and
attenuated SAA1-induced Il6 expression in myotubes as well
as NF-κB p65 phosphorylation in muscle of septic mice. These
data indicate that BMS-345541 effectively inhibited NF-κB
activity in myocytes. In addition, BMS-345541 attenuated
myotube atrophy as well as the SAA1-induced molecular
changes consistently described as atrophic response with an
increase in MuRF1 and a decrease in MyHC.34,48,64–66 Our
results indicate that SAA1-induced atrophy was mediated
by NF-κB. Of note, NF-κB p65 was shown to mediate
denervation and tumour-induced muscle atrophy,52,53 and
its inhibition prevented atrophy in a mouse model of acute
lung injury.54 Our data corroborate and extend these findings
(i) by demonstrating that NF-κB has an important role in
sepsis-induced atrophy as well and (ii) by identifying SAA1
as a facilitator of the NF-κB p65 pathway, which mediates
most of its effects on myocytes in vitro.
To investigate if NF-κB inhibition prevents sepsis-induced
muscle atrophy in vivo, we tested BMS-34554141 in the CLP
mouse model. The expression of many pro-inflammatory
genes is regulated by NF-κB. NF-κB normally resides in
the cytoplasm of unstimulated cells as an inactive complex
with a member of the IκB inhibitory protein family. This
class of protein includes IκBα, IκBβ, and IκBε, which all
form a complex with NF-κB (for a review, see Whiteside
and Israel67). Stimulation of cells with compounds that
activate NF-κB-dependent gene expression results in the
phosphorylation of IκBα at Ser-32 and Ser-36.68 This is critical
for subsequent ubiquitination and proteolysis of IκBα,
which then leaves NF-κB free to translocate to the nucleus
and promote gene expression.69 Analogous serines have
been identified in both IκBβ and IκBε, and phosphorylation
at these residues appears to regulate the proteolytic
degradation of these proteins by a mechanism similar to that
of IκBα.70 Phosphorylation of IκBα at Ser-32 and Ser-36 is
mediated by a high molecular mass (500–900 kDa)
multisubunit IκB kinase (termed IKK).71 Two catalytic
subunits (termed IKK-1 and IKK-2) of IKK have recently
been identified.72 Several working groups have shown
that all known pro-inflammatory stimuli, including cytokines,
viruses, and LPS, require IKK for NF-κB activation (for a
Figure 8 BMS-345541 treatment attenuates sepsis-induced protein degradation. Eighteen-week-old male WT mice were Sham or CLP operated. Mice
received vehicle or BMS-345541 (30 mg/kg) 30 min prior surgery and 6 h later vehicle or BMS-345541 (15 mg/kg) by oral gavage. After 96 h, the mice
were sacrificed. (A and B) Sham + vehicle (n = 6), CLP + vehicle (n = 4), sham + BMS-345541 (n = 6), and CLP + BMS-345531 (n = 11). (A) qRT-PCR
analysis of myosin heavy chain (Myh) 4 and Myh7 expression in tibialis anterior muscle. mRNA expression was normalized to Gapdh. (B) qRT-PCR
analysis of Trim63/MuRF1, Fbxo32/Atrogin1, and Fbxo30/MuSA1 expression in tibialis anterior and gastrocnemius/plantaris muscle. mRNA expression
was normalized to Gapdh. Data are presented as fold change ± SEM. *P ≤ 0.05 and **P ≤ 0.01. (C) Western blot analysis of proteins isolated from
tibialis anterior with anti-MuRF1 and anti-Atrogin1 antibody. GAPDH was used as loading control.
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review, see Ghosh and Karin73). Previously, BMS-345541, a
highly selective cell permeable IKK-2 and IKK-1 inhibitor that
inhibits NF-κB-dependent transcription of pro-inflammatory
cytokines both in vitro and in vivo was identified.
Subsequently, BMS-345541 was shown to attenuate
LPS-induced production of TNF, IL1β, IL8, and IL6 in THP-1
cells.41 BMS-345541 was also shown to abolish TNF-stimulated
IκBα-phosphorylation in THP-1 cells41 and the prostate cancer
cell line PC-3.46 BMS-345541 was previously shown to reduce
CLP and LPS-induced lung injury,42,43 to reduce inflammation
in rats with spinal cord injury, and to suppress inflammation
in a model of cardiac graft rejection.44,45 Due to its high
bioavailability41 and its anti-inflammatory characteristics
without impairing immune cell activation42 and bacterial
clearance, BMS-345541 was well suited for our studies.
Indeed, we show that NF-κB p65 was activated in muscle of
septic mice, which is in accordance with previously published
work demonstrating NF-κB activation in muscle of CLP
operated rats.74 Next, we confirmed that BMS-345541
prevented activation of NF-κB p65 in muscle of septic mice,
which is in line with a recent report where BMS-345541
was shown to inhibit LPS-induced NF-κB-dependent gene
expression in mice41 and proves its biological activity.
Interestingly, BMS-345541 treatment resulted in a 63%
percent higher survival rate of septic mice. Because increased
NF-κB activity in peripheral blood mononuclear cells
predicted fatal outcome in septic patients and inhibition of
the IKK-NF-κB axis was shown to increase survival in an
LPS-induced toxic shock model in mice,75 this result was
somewhat expected. Importantly, BMS-345541 reduced the
degree of sepsis-induced muscle atrophy. Accordingly,
sepsis-induced reduction in Myh4 expression and induction
of Trim63/MuRF1 and Fbxo32/Atrogin1 expression was
reversed by BMS-345541. MuRF1 mediates proteasomal
degradation of muscular proteins, like MyHC2 and 4,64 and
as an atrophy marker is increased in muscle of septic
Figure 9 Proposed mechanism of serum amyloid A 1 (SAA1) induced muscle atrophy. SAA1 binds to muscular Toll-like receptors (TLR) 2 and 4, which
results in an activation of the canonical NF-κB p65 pathway leading to NF-κB p65/RelA phosphorylation and its translocation into the nucleus. In the
nucleus, NF-κB p65/RelA binds to NF-κB response elements (NRE), which leads to increased expression and secretion of the pro-inflammatory cytokine
Il6. IL6 in turn induces expression and secretion of SAA1 resulting in a positive feedback loop. In addition, SAA1 causes an increase of MuRF1/Trim63
and Atrogin1/Fbxo32, which mediate muscle atrophy in sepsis. Anti-TLR2 or anti-TLR4 antibodies inhibit SAA1-induced Il6 expression. The specific IκB
kinase subunit IKK-2 inhibitor BMS-345541 inhibits SAA1-induced and NF-κB dependent gene expression, thereby reducing SAA1-mediated atrophy
and inhibiting the self-augmenting SAA1-IL6 feedback loop.
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patients and mice.34,37 A previous report showed that mice
overexpressing activated IKK2 in muscle, which increases
NF-κB activity, displayed increased MuRF1 expression and
aggravated muscle atrophy. When these mice were crossed
to MuRF1 knockout mice, atrophy was greatly reduced.52
Together with our report, these data suggest that NF-κB
signalling contributes to sepsis-induced muscle atrophy, which
involves MuRF1-dependent protein degradation.
Our data implicate that inhibition of NF-κB by
BMS-345541 could be effective to decrease muscle wasting
in sepsis. Because NF-κB is a key regulator of inflammatory
responses and involved in other forms of muscle
wasting,52,53,76 we hypothesize that BMS-345541 could be
useful to prevent or treat other forms of muscle wasting
as well. For example, end-stage cancer patients often suffer
from cachexia, which is accompanied with a poor prognosis.
Among the best studied inflammatory cytokines promoting
cancer cachexia are TNF, IL6,77 IL1, and interferon gamma,78
which are all elevated79 and may together trigger muscle
wasting by increasing NF-κB activity.80–82 For instance, TNF
promotes anorexia83 and skeletal muscle wasting mainly
through activation of the NF-κB pathway.84 However, the
precise mechanism how NF-κB mediates muscle wasting in
cancer is less well understood. One explanation is that
NF-κB signalling and UPS-mediated protein degradation are
closely connected to each other. On one side, NF-κB
increases the expression of atrogenes and proteasome-
mediated protein degradation in muscle. On the other side,
proteasome inhibitors interfere with the NF-κB pathway
because they inhibit IκB degradation, which in turn prevents
NF-κB activation.85 Accordingly, an increased Fbxo32/
Atrogin1 gene expression86 and protein ubiquitination86
was associated with an activated UPS in a rat model of
cachexia, induced by the Yoshida ascites hepatoma cells. In
tumour-bearing mice, this UPS activation was mediated by
an increased NF-κB activity, which stimulated Trim63/MuRF1
expression and muscle wasting.52 These data implicate that
NF-κB inhibition could be useful to prevent cancer cachexia.
Indeed, synthetic double-stranded oligodeoxynucleotides,
which block NF-κB binding to promoter regions, inhibited
cachexia in a mouse tumour model.87 However, if
BMS-3445541 is useful to prevent muscle wasting in cancer
needs to be shown in the future. Furthermore, because NF-κ
B activation is important for denervation-induced muscle
wasting, many approaches were undertaken to reduce its
activity to attenuate this phenotype. For example,
misexpression of IκB that was used to inhibit NF-κB
activity reduced denervation-induced muscle wasting in
tumour-bearing mice.52 Denervation-induced atrophy was
also attenuated in mice lacking IKKβ.53 Inhibition of NF-κB
by BMS-3445541 could therefore be useful to prevent
denervation-induced muscle wasting as well.
Finally, and in agreement with previous reports,42
BMS-345541 did not affect the immune cell responses to
sepsis.42 In summary, our data indicate that inhibition of
the IKK-NF-κB pathway holds promise to prevent both
mortality and muscle atrophy in sepsis.
Conclusions
During sepsis, SAA1 is increased in muscle and directly acts on
myocytes via the TLR2/TLR4/NF-κB p65 axis. Blockade of
SAA1-mediated NF-κB activation by BMS-345541 attenuated
atrophy and inhibited the SAA1-IL6 feedback loop in
myocytes in vitro. Likewise, BMS-345541 increased survival
and attenuated skeletal muscle atrophy in septic mice
(Figure 9). We suggest that monitoring SAA1 and inhibition
of the SAA1/TLR2/TLR4/NF-κB atrophy pathway could
ameliorate ICUAW. Further studies are needed to determine
how the SAA1 pathway is mechanistically connected to
other atrophy pathways such as MuRF1 and Atrogin1 that
we found to be affected.
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